Company Contents
Quick Facts & Snapshot
Summary
The global breast biopsy devices market is in a scale-up phase, driven by rising breast cancer screening volumes, demand for minimally invasive procedures, and hospital focus on workflow efficiency and safety. Leading manufacturers consolidate share through integrated imaging-biopsy platforms, while niche innovators target automation gaps. From 2025 to 2032, the market expands from US$ 1.77 Billion to US$ 2.92 Billion at a 7.30% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
Rankings of Breast Biopsy Devices market companies are built from a composite score that blends quantitative and qualitative indicators. Core metrics include estimated 2025 breast biopsy device revenue, multi-year growth, and installed base across hospitals, imaging centers, and outpatient clinics. We also consider technology differentiation in vacuum-assisted, core needle, stereotactic, MRI-guided, and ultrasound-guided systems, along with breadth of probes, needles, and localization accessories. Service coverage, uptime guarantees, and ability to support long-term maintenance and training contracts weigh heavily, as do regulatory approvals and post-market surveillance performance. Strategic criteria capture project wins with major health systems, portfolio integration with imaging modalities, AI-enabled workflow tools, and emerging-market penetration. Each company receives a normalized score, benchmarked against peers; final ranks reflect overall competitive strength in the global breast biopsy devices landscape.
Top 10 Companies in Breast Biopsy Devices
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Hologic, Inc.
Hologic is a global women’s health leader, integrating breast imaging, biopsy devices, and analytics into comprehensive diagnostic ecosystems.
BD (Becton, Dickinson and Company)
BD is a diversified medtech supplier known for biopsy needles and disposables that support high-volume breast imaging and intervention workflows.
Devicor Medical Products (Leica Biosystems / Danaher)
Devicor, under Leica Biosystems, focuses on vacuum-assisted breast biopsy systems seamlessly linked to pathology workflows and diagnostics.
Siemens Healthineers AG
Siemens Healthineers provides imaging-led breast biopsy solutions integrated into mammography and MRI platforms for streamlined diagnostic workflows.
GE HealthCare Technologies Inc.
GE HealthCare delivers stereotactic and contrast-enhanced biopsy capabilities on its mammography and ultrasound platforms, emphasizing patient comfort and workflow.
Ethicon Endo-Surgery (Johnson & Johnson MedTech)
Ethicon focuses on breast biopsy and surgical tools that span core needle sampling to breast-conserving surgical interventions.
Argon Medical Devices, Inc.
Argon Medical provides biopsy needles and oncology tools aimed at interventional radiologists and community hospitals requiring robust, cost-effective solutions.
Cook Medical LLC
Cook Medical offers core biopsy instruments and accessories positioned for interventional radiology and multi-organ biopsy use, including breast.
STERYLAB S.r.l.
STERYLAB is a European specialist in disposable breast biopsy guns and localization devices aimed at cost-conscious hospitals.
Scion Medical Technologies, LLC
Scion Medical develops specialty vacuum-assisted and soft-tissue biopsy devices, frequently partnering as an OEM supplier.
SWOT Leaders
Hologic, Inc.
SWOT Snapshot
Market-leading installed base in breast imaging, strong brand in women’s health, tightly integrated imaging-biopsy ecosystem and AI tools.
Premium pricing can limit penetration in cost-constrained markets, and reliance on mature U.S. segment increases reimbursement sensitivity.
Screening expansion in Asia and Latin America, upgrades from 2D to 3D plus biopsy, and broader adoption of AI-enabled targeting.
Intensifying competition from integrated imaging rivals, procurement-driven price pressures, and potential regulatory changes around screening guidelines.
BD (Becton, Dickinson and Company)
SWOT Snapshot
Global scale in disposables, strong relationships with procurement teams, broad biopsy needle portfolio spanning multiple price tiers.
Less ownership of capital imaging-biopsy platforms, limiting ecosystem control and advanced workflow integration versus full-line competitors.
Growing procedure volumes in emerging markets, hospital standardization of biopsy kits, and expansion into ambulatory and outpatient imaging centers.
Commoditization of needles due to low-cost entrants, stringent quality regulations, and volume-based tenders compressing margins in developed markets.
Devicor Medical Products (Leica Biosystems / Danaher)
SWOT Snapshot
Strong reputation for Mammotome systems, integration with pathology workflows, and deep relationships with specialist breast centers.
Portfolio concentrated in vacuum-assisted devices, and comparatively smaller scale than diversified giants limiting negotiating leverage.
Rising demand for end-to-end diagnostic pathways, digital pathology growth, and increased use of vacuum-assisted biopsy in complex cases.
Imaging majors bundling biopsy with modality sales, reimbursement uncertainty for advanced procedures, and potential shifts toward alternative localization techniques.
Breast Biopsy Devices Market Regional Competitive Landscape
North America remains the largest and most mature market, driven by high screening coverage, robust reimbursement, and rapid technology adoption. Hologic, BD, Devicor, and GE HealthCare anchor premium segments, while Argon and Scion target community hospitals. Breast Biopsy Devices market companies increasingly bundle service, analytics, and training to secure multiyear system-wide contracts.
In Western Europe, Siemens Healthineers, Hologic, GE HealthCare, and Devicor compete closely, supported by strong public screening programs and centralized breast units. Cost containment and value-based procurement favor vendors with lifecycle cost transparency. STERYLAB leverages competitive pricing in Southern Europe, while BD and Cook Medical strengthen disposable needle positions across regional purchasing groups.
Asia Pacific delivers the fastest growth, with rising awareness, government-led screening initiatives, and expanding private hospital chains. Hologic and GE HealthCare win premium installations in Japan, South Korea, and Australia, whereas BD and Argon supply mid-tier devices in Southeast Asia and India. Breast Biopsy Devices market companies increasingly localize training and service operations to support rapid capacity build-out.
Latin America and the Middle East & North Africa show uneven but improving access to breast imaging and biopsy. BD, Argon, and STERYLAB capture share through competitively priced needles and guns, while Siemens Healthineers and GE HealthCare supply integrated imaging-biopsy systems to flagship centers. Currency volatility and financing constraints push vendors toward flexible leasing and pay-per-use models.
Central and Eastern Europe, along with some CIS markets, are upgrading aging mammography fleets and introducing organized screening pilots. Siemens Healthineers, GE HealthCare, and Hologic compete for reference projects, frequently supported by international funding. Breast Biopsy Devices market companies that offer modular upgrades and retrofit-friendly biopsy solutions gain traction amid constrained capital budgets.
Challengers & Emerging Players
Emerging Challengers & Disruptive Start-Ups
Developing compact, AI-assisted vacuum-assisted breast biopsy platforms designed to retrofit onto existing mammography systems with minimal workflow disruption.
Specializes in smart biopsy needles with embedded sensors for real-time tissue characterization, aiming to reduce repeat procedures and inconclusive samples.
Combines high-resolution ultrasound with robotic needle guidance, targeting outpatient centers needing affordable, semi-automated breast biopsy solutions.
Offers low-cost localization wires and biopsy guns tailored to resource-constrained hospitals, emphasizing sterility, simplicity, and compatibility with popular imaging systems.
Cloud-based decision-support platform that integrates biopsy device data with digital pathology images to optimize sampling strategies and reporting efficiency.
Breast Biopsy Devices Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Breast Biopsy Devices market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Breast Biopsy Devicesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.